Performance of a Commercial Immunoglobulin M Antibody Capture Assay Using Analyte-Specific Reagents To Screen for Interfering Factors during a West Nile Virus Epidemic Season in Nebraska

Authors

• Anthony R. Sambol, Nebraska Public Health Laboratory, Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, Nebraska
• Steven H. Hinrichs, Nebraska Public Health Laboratory, Department of Pathology and Microbiology, University of Nebraska Medical CenterFollow
• Wayne R. Hogrefe, Focus Diagnostics, 5785 Corporate Ave., Cypress, California
• Beth K. Schweitzer, Nebraska Public Health Laboratory, Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, Nebraska

Date of this Version

1-2007

Comments

Published in CLINICAL AND VACCINE IMMUNOLOGY, Jan. 2007, p. 87–89 Vol. 14, No. 1.

Abstract

In 2003, the Nebraska Public Health Laboratory tested more than 10,371 serum and 516 cerebral spinal fluid specimens. Results showed that without performing the interfering factors screen for specimens in the low positive index value range of >1.1 to ≤3.5, a false positivity rate of 6.5% would have been realized.